Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mocetinostat in Relapsed/Refractory Lymphoma
NCT00359086Phase 2Completed
- Sponsor
- Mirati Therapeutics
- Start
- Aug 2006
- Primary completion
- Jan 2012
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of mocetinostat in diffuse large B-cell lymphoma (DLBCL), Follicular lymphoma (FL), sponsored by Mirati Therapeutics. Started Aug 2006; status: completed.
02
Drugs
mocetinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)Follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00359086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00359086.